Why Lenacapavir is Important … and Expensive
Lenacapavir has the potential to transform HIV care and prevention, but only if access is broadened, according to Jose Abrigo, Esq., HIV Project Director of the Lambda Legal Defense and Education Fund.
Injectable lenacapavir, the investigational twice-yearly antiretroviral, has created quite the buzz this year, reporting an almost 100% success rate at preventing HIV in clinical trials, when compared to placebo. However, this success comes with a price, up to $44,819 per person per year, according to an article published in the Journal of Antimicrobial Chemotherapy.
This price tag is expected to cause access issues, according to Jose Abrigo, Esq., HIV Project Director of the Lambda Legal Defense and Education Fund.
“Insurers are disincentivized to cover really expensive drugs,” Abrigo said in an interview with Managed Healthcare Executive. “Because insurance companies don't want to spend money, if there is a viable alternative, they will deny it and say, ‘take the others.’ That analysis isn't fully informed sometimes because sometimes the medical records submitted to them are incomplete, doctors don't know how to word the request and just the default for most insurers to deny.”
Lenacapavir is already FDA-approved for patients with drug resistant HIV, under the brand name Sunlenca.
FDA Accepts NDA for Gilead's New HIV Prevention Shot
February 18th 2025Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving this drug a priority review and expects to make a decision by June 19, 2025, according to a release.
Read More
HIV + Hepatitis Institute Welcomes RFK, Talks Importance of Ending the HIV Epidemic
February 13th 2025The group released a statement today expressing that they are eager to work with Robert F. Kennedy Jr. to eradicate HIV when steps into his role as the Secretary of Health and Human Services.
Read More
Trump Administration Throws U.S. AIDS Support into Turmoil
February 6th 2025PEPFAR, the main U.S.-funded global AIDS program was given a waiver from the foreign aid freeze, but there is still uncertainty and interruptions, partly because many PEPFAR programs are implemented through USAID, which has been largely shutdown by the news administration.
Read More
RFK Jr. and HIV Denial: He Says He Is Neutral, But...
January 29th 2025In 2021 book attacking Anthony Fauci, M.D., Robert F. Kennedy Jr. casts doubt on HIV being the sole cause of AIDS and presents arguments made by "HIV deniers" that believe it is bystander in the immunosuppression that characterizes AIDS.
Read More
